Related Experiment Video
Updated: Jul 6, 2026
06:29
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
Aurora kinases as anticancer drug targets.
Oliver Gautschi1, Jim Heighway, Philip C Mack
1Department of Medical Oncology, Bern University Hospital, Bern, Switzerland.
Summary
Aurora kinases are crucial for cell division, and their dysfunction is linked to cancer. Small-molecule inhibitors show promise as antineoplastic agents, with ongoing research focusing on optimizing their use.
Area of Science:
- Cell Biology
- Molecular Oncology
Background:
- Aurora kinases (A, B, and C) are serine-threonine kinases vital for mitosis.
- Dysregulation of aurora kinases is implicated in aneuploidy, mitotic arrest, and cell death.
- Elevated expression of Aurora A and B is frequently observed in various cancers, correlating with poor prognosis and genetic instability.
Purpose of the Study:
- To review recent preclinical and clinical data on aurora kinase inhibitors.
- To discuss emerging directions in the development of aurora kinase inhibitors as antineoplastic agents.
Main Methods:
- Review of preclinical studies on small-molecule aurora kinase inhibitors.
- Analysis of preliminary clinical trial data (Phase I) for aurora kinase inhibitors.
- Discussion of challenges and future directions in the field.
Main Results:
- Small-molecule aurora kinase inhibitors demonstrate preclinical activity against solid tumors.
- Clinical trials show cytostatic effects and disease stabilization in solid tumors.
- Objective responses observed in leukemia patients, potentially due to off-target effects (Abl kinase inhibition).
Conclusions:
- Aurora kinase inhibitors represent a promising class of antineoplastic agents.
- Further research is needed to optimize drug administration and identify biomarkers for patient selection.
- Combination therapies with cytotoxic drugs warrant investigation.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...